Cardiome Pharma Corp.
Phase IIa study for oral RSD1235 initiated in patients with atrial fibrillation
Published in Cardiovascular Business Week, January 10th, 2006
The double-blind, placebo-controlled, randomized, dose-ranging study will measure the safety and efficacy of oral RSD1235 over 28 days of oral dosing in patients at risk of recurrent atrial fibrillation. It is expected that the majority of patients enrolled will have experienced atrial fibrillation for greater than 30 days and less than 180 days in duration. The study will enroll 180 patients across 75 centers in Canada, U.S. and Europe.
Patients with atrial fibrillation in the first stage of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
More Articles from Cardiovascular Business Week
- Best Practices, LLC
Market research study shows profitable pharma partnerships are mutually beneficial - Biophan Technologies, Inc.
Medical device company accelerates commercialization of Myo-Vad cardiac assist device - CardioMag Imaging, Inc.
Cardiology visualization device developer confirms trading on London's Stock Exchange - Healthcare Coverage
Wockhardt Hospitals in India and Cigna streamline healthcare payment for expatriates - Ospedale San Giovanni Bellinzona
Researchers report details of new studies and findings in the area of Cancer Therapy - Aarhus University Hospital
Alpha-linolenic acid has positive effect on heart rate variability in women - More from this issue of Cardiovascular Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
